Here are five key points:
1. The market was valued at $5.06 billion in 2016, and is set to grow to $13.56 billion by 2021.
2. A growing aging population and increasing research and development advancements will spur market growth, among other factors.
3. Evolving regulatory guidelines and ethical laws regarding tissue and cell-based products serve as barriers to market growth.
4. In 2016, the orthopedic and musculoskeletal spine segment captured the largest share of the Europe regenerative medicines market.
5. Dominant market players include Vertex Pharmaceuticals, Acelity, Celgene Corp., StemCells, Organogenesis, NuVasive, Vericel Corp., Japan Tissue Engineering Co., Cytori Therapeutics, Advantagene and Mesoblast.
More articles on biologics:
MiMedx cautions CEO imposter emails: 5 things to know
Cerapedics, DSM Biomedical partner for next generation peptide enhanced bone graft: 5 key notes
Stem Cell Center Network to open 5th US location: 5 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
